Oncology

Latest News

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

By Jared Kaltwasser

May 7th 2025

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Community Oncology Reacts to Trump's Drug Pricing Executive Order

By Maggie L. Shaw

May 2nd 2025

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com

5 Things You Should Know About Skin Cancer

By Pearl Steinzor

May 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 31st 2019

ASCO Names "Progress in Treating Rare Cancers" as the Advance of the Year

Jaime Rosenberg

Reflecting on a year of breakthrough advancements in the treatment of rare, difficult to treat cancers, the American Society of Clinical Oncology (ASCO) has named “Progress in Treating Rare Cancers” as the Advance of the Year.

January 30th 2019

Discussing the Continuing Decline in Overall Cancer Mortality in the United States

In this podcast, we speak with Rebecca Siegel, MPH, strategic director of surveillance information services in the Intramural Research Department at the American Cancer Society, and the lead author of the annual Cancer Statistics report that estimates the number of new cancer cases and deaths in the United States each year.

January 30th 2019

Mantle Cell Lymphoma (MCL): Treatment Landscape and Access to Care

https://www.pharmacytimes.org/on-demand/mantle-cell-lymphoma-mcl-treatment-landscape-and-access-to-care

January 29th 2019

Care Coordination Is the Top Investment Cancer Programs Can Make, Respondents Say

Laura Joszt, MA

The ninth annual Trending Now in Cancer Care survey identified current and emerging trends for US cancer programs, such as the ongoing threat of drug costs and popular services progams are planning to add in the next 2 years.

January 29th 2019

FDA Approves Ibrutinib Combination as Frontline Treatment for CLL

Jaime Rosenberg

The approval marks the first non-chemotherapy combination regimen for the treatment of patients with chronic lymphocytic leukemia (CLL).

January 23rd 2019

Managed Care Considerations in Meeting the Complex Needs of Patients with Pancreatic Cancer

https://www.pharmacytimes.org/on-demand/managed-care-considerations-in-meeting-the-complex-needs-of-patients-with-pancreatic-cancer

January 22nd 2019

Treatment Advances Make Supportive Care More Important in Multiple Myeloma

Laura Joszt, MA

As patients with multiple myeloma live longer thanks to advancements in treatments, more attention is being paid to treatment-related toxicities that are becoming more relevant.

January 20th 2019

Podcast: This Week in Managed Care—New Drug Pricing Probe and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

January 20th 2019

Dr Sibel Blau Discusses the Role of the Quality Cancer Care Alliance

As the first clinically integrated oncology network, the Quality Cancer Care Alliance (QCCA) brings together the best practices and shares knowledge on value-based care, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.

January 19th 2019

Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy

Jaime Rosenberg

Higher tumor mutational burden is associated with improved overall survival in patients with stage IV or metastatic disease being treated with immune checkpoint inhibitors.

January 19th 2019

Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose

Laura Joszt, MA

Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients. In an analysis of 2 studies, patients with high-risk MM had improved outcomes when taking carfilzomib once a week compared with a twice-weekly dose.

January 19th 2019

AJMCtv® Interviews, January 2019

Samantha DiGrande Jaime Rosenberg

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

January 19th 2019

Policy

Updates from the annual ASH meeting, December 2018.

January 18th 2019

This Week in Managed Care: January 18, 2019

This week, the top managed care news included a new investigation into drug prices; FDA Commissioner Scott Gottlieb, MD, provided updates on how the government shutdown is impacting FDA work; research found comorbidities impede clinical trial participation for patients with cancer.

January 18th 2019

Quality of Life

Updates from the annual ASH meeting, December 2018.

January 18th 2019

USPSTF Releases Draft Recommendation on Drugs to Lower Risk of Breast Cancer

Samantha DiGrande

Earlier this week, the US Preventive Services Task Force (USPSTF) released a draft guidance recommendations on medications for women at an increased risk for breast cancer.

January 18th 2019

Cost of Care: Biosimilars

Updates from the annual ASH meeting, December 2018.

January 18th 2019

Cost of Care

Updates from the annual ASH meeting, December 2018.

January 17th 2019

Clinical: Lymphoma

Updates from the annual ASH meeting, December 2018.

January 17th 2019

Clinical: Myelofibrosis

Updates from annual ASH meeting, December 2018.

January 17th 2019

Clinical: Chronic Lymphocytic Leukemia

Updates from the annual ASH meeting, December 2018.

January 17th 2019

Clinical: Multiple Myeloma

Updates from the annual ASH meeting, December 2018.

January 17th 2019

Clinical: CAR T-Cell Therapy

Updates from the Annual ASH meeting, December 2018.

January 16th 2019

African American Women Are at a Disadvantage in Preventing Breast Cancer

Kelly Davio

Breast cancer risk estimation models identify women who are at high risk based on a variety of factors, and women who are identified as being at high risk may be able to reduce their chance of breast cancer through preventative measures such as prophylactic surgeries or chemoprevention medications. However, uptake of these preventative treatments varies among racial groups, new research from The Ohio State University finds that racial disparities in healthcare are to blame.

January 16th 2019

Comorbidities Impede Clinical Trial Participation Among Patients With Cancer

Jaime Rosenberg

Patients with cancer who have comorbidities are less likely to have clinical trial discussions, be offered a clinical trial, and participate in a clinical trial, according to a new study.

January 13th 2019

Podcast: This Week in Managed Care—Coverage From the JP Morgan Healthcare Conference and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

January 11th 2019

This Week in Managed Care: January 11, 2019

This week, the top managed care news included the FDA commissioner discussing boosting drug competition; BMS offering details on its acquisition of Celgene; and cancer mortality rates declining for the 25th consecutive year.

January 10th 2019

Cervical Cancer Screening Rates "Unacceptably Low," Researchers Find

Jaime Rosenberg

Less than two-thirds of women aged 30 to 65 years were up to date with cervical cancer screenings in 2016. The percentage was even lower for women aged 21 to 29, with just over half up to date on screenings.

January 9th 2019

Cancer Mortality Rate Drops for the 25th Consecutive Year, but Socioeconomic Gap Widens

Kelly Davio

For the 25th consecutive year, the cancer mortality rate in the United States has declined, according to The American Cancer Society’s annual report on cancer rates and trends. The overall 27% drop in mortality rate translates into 2.6 million fewer deaths from cancer between the years 1991 and 2016.

January 9th 2019

What We're Reading: NYC Expands Health Coverage; Hospital Transparency Rule Confusion; Eli Lilly Purchases Loxo Oncology

AJMC Staff

New York City is expanding health coverage to 600,000 uninsured residents; a transparency rule requiring hospitals to post prices online is confusing patients; and Eli Lilly has purchased Loxo Oncology in what some are calling a massive bet on cancer genetic.

...

30 31 32 33 34 35 36 37 38

...

184 >